2 Xideas Ag Halozyme Therapeutics, Inc. Transaction History
2 Xideas Ag
- $614 Million
- Q1 2025
A detailed history of 2 Xideas Ag transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, 2 Xideas Ag holds 246,802 shares of HALO stock, worth $13 Million. This represents 2.57% of its overall portfolio holdings.
Number of Shares
246,802
Previous 379,240
34.92%
Holding current value
$13 Million
Previous $18.1 Million
13.14%
% of portfolio
2.57%
Previous 2.67%
Shares
12 transactions
Others Institutions Holding HALO
# of Institutions
594Shares Held
124MCall Options Held
320KPut Options Held
113K-
Black Rock Inc. New York, NY17.6MShares$930 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$678 Million0.02% of portfolio
-
State Street Corp Boston, MA6.05MShares$320 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA3.89MShares$206 Million0.05% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.67MShares$194 Million5.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.35B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...